Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino... see more

Recent & Breaking News (NDAQ:ACAD)

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Business Wire 11 days ago

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Business Wire December 18, 2025

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Business Wire December 12, 2025

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Business Wire November 20, 2025

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Business Wire November 5, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire November 1, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 31, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 30, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 29, 2025

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire October 28, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

PR Newswire October 28, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

PR Newswire October 23, 2025

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Business Wire October 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 21, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 20, 2025

Podcasts